Pfizer (PFE)

34.65 +0.17 (0.49%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/30/19 *Est.)
- M&A (6/30/20 *Est)

Latest Headlines

Form 4 PFIZER INC For: Aug 15 Filed by: ROGERS DAWN August 16, 2019 4:05 PM - SEC Filing Form 4 PFIZER INC For: Aug 15 Filed by: YOUNG JOHN D August 16, 2019 4:05 PM - SEC Filing Form 4 PFIZER INC For: Aug 15 Filed by: BOURLA ALBERT August 16, 2019 4:05 PM - SEC Filing Form 4 PFIZER INC For: Aug 15 Filed by: JOHNSON RADY A August 16, 2019 4:05 PM - SEC Filing Form 4 PFIZER INC For: Aug 14 Filed by: LANKLER DOUGLAS M August 15, 2019 3:17 PM - SEC Filing Form 4 PFIZER INC For: Aug 14 Filed by: BOURLA ALBERT August 15, 2019 3:17 PM - SEC Filing Vaccinex (VCNX) Reports Full Enrollment in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO (avelumab) August 13, 2019 8:07 AM - StreetInsider Form S-8 PFIZER INC August 9, 2019 10:10 AM - SEC Filing Form S-8 POS PFIZER INC August 9, 2019 6:03 AM - SEC Filing Sarepta says adverse event report for DMD gene therapy erroneously submitted August 8, 2019 7:50 PM - StreetInsider Form 10-Q PFIZER INC For: Jun 30 August 8, 2019 4:26 PM - SEC Filing Form 8-K PFIZER INC For: Jul 31 August 5, 2019 4:29 PM - SEC Filing Pre-Open Movers 08/05: (ALLK) (MBIO) (TXT) Higher; (GLYC) (CARS) (DO) (more...) August 5, 2019 9:22 AM - StreetInsider GlycoMimetics (GLYC) Announces Pfizer's (PFE) Phase 3 Clinical Trial Evaluating Rivipansel in SCD Did Not Meet Endpoints (Earlier) August 5, 2019 6:18 AM - StreetInsider GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease   August 2, 2019 8:43 PM - BizWire Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis August 2, 2019 6:49 PM - BizWire Form 4 PFIZER INC For: Jul 31 Filed by: YOUNG JOHN D August 2, 2019 4:29 PM - SEC Filing Form 4 PFIZER INC For: Jul 31 Filed by: ROGERS DAWN August 2, 2019 4:29 PM - SEC Filing Form 4 PFIZER INC For: Jul 31 Filed by: BOURLA ALBERT August 2, 2019 4:28 PM - SEC Filing Form 4 PFIZER INC For: Jul 31 Filed by: JOHNSON RADY A August 2, 2019 4:28 PM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC August 2, 2019 6:05 AM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC August 1, 2019 5:29 PM - SEC Filing Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company August 1, 2019 12:16 AM - BizWire Form 425 PFIZER INC Filed by: PFIZER INC July 31, 2019 5:27 PM - SEC Filing BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc. July 31, 2019 7:09 AM - PR NewsWire Form 425 PFIZER INC Filed by: PFIZER INC July 30, 2019 5:31 PM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC July 30, 2019 5:30 PM - SEC Filing Popular stocks with increasing unusual volume: PFE BYND T July 30, 2019 9:47 AM - StreetInsider Pfizer (PFE) Off Worst Level But Still Down 4.5% Following Downgrades July 30, 2019 9:45 AM - StreetInsider Five Years on, 3.9 Million People in the Developing World Have Access to HIV Treatment Dolutegravir, Thanks to Access-oriented Voluntary Licensing Agreements July 30, 2019 8:57 AM - PR NewsWire Tech pulls Wall Street lower on Trump trade warning July 30, 2019 8:18 AM - StreetInsider Pfizer (PFE) Completes Acquisition of Array Biopharma (ARRY) July 30, 2019 8:17 AM - StreetInsider Pfizer Completes Acquisition of Array Biopharma July 30, 2019 8:16 AM - BizWire BofA/Merrill Lynch Downgrades Pfizer (PFE) to Neutral July 30, 2019 6:18 AM - StreetInsider UPDATE: Morgan Stanley Downgrades Pfizer (PFE) to Equalweight July 30, 2019 4:51 AM - StreetInsider Mylan deal puts future of its beleaguered EpiPen in spotlight July 29, 2019 6:00 PM - StreetInsider Mylan stock boost follows long share struggles for company, generics industry July 29, 2019 5:45 PM - StreetInsider Form 425 PFIZER INC Filed by: PFIZER INC July 29, 2019 5:23 PM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC July 29, 2019 5:23 PM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC July 29, 2019 5:22 PM - SEC Filing JPMorgan Says Upjohn/Mylan NewCo is Worth $25-$32 per share (PFE) (MYL) July 29, 2019 11:52 AM - StreetInsider Pfizer (PFE) option implied volatility flat into EPS July 29, 2019 10:50 AM - StreetInsider Pfizer (PFE) Mylan (MYL) option implied volatility after announcing Pfizer (PFE) deal to merge off-patent business with Mylan (MYL) July 29, 2019 10:09 AM - StreetInsider Mylan Peers Gain Following Deal July 29, 2019 9:30 AM - StreetInsider Pre-Open Movers 07/29: (TYME) (MCC) (MYL) Higher; (LXRX) (ONDK) (CTB) (more...) July 29, 2019 9:28 AM - StreetInsider Form 8-K PFIZER INC For: Jul 29 July 29, 2019 8:42 AM - SEC Filing Form 8-K PFIZER INC For: Jul 29 July 29, 2019 8:33 AM - SEC Filing Form 425 PFIZER INC Filed by: PFIZER INC July 29, 2019 8:31 AM - SEC Filing Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal July 29, 2019 7:38 AM - StreetInsider Pfizer posts 30% rise in quarterly profit July 29, 2019 7:06 AM - StreetInsider Pfizer to spinoff, merge off-patent drugs unit with Mylan July 29, 2019 7:01 AM - StreetInsider UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance July 29, 2019 6:51 AM - StreetInsider Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT July 29, 2019 6:50 AM - BizWire Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine July 29, 2019 6:46 AM - StreetInsider PFIZER REPORTS SECOND-QUARTER 2019 RESULTS  July 29, 2019 6:46 AM - BizWire Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine July 29, 2019 6:45 AM - BizWire Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine July 29, 2019 6:45 AM - PR NewsWire Mylan (MYL) Mentions Potential Pfizer (PFE) Deal in Forward Looking Statement with Earnings Release July 29, 2019 6:38 AM - StreetInsider Potential Mylan (MYL)/Upjohn (PFE) Merger a 'Goldilocks Scenario' - Mizuho July 29, 2019 6:27 AM - StreetInsider ViiV Healthcare Reports Submission of Regulatory Application to EMA for Investigational Cabotegravir to Be Used in Combination With Rilpivirine July 29, 2019 6:00 AM - StreetInsider Pfizer (PFE) option implied volatility at low end of range July 29, 2019 4:01 AM - StreetInsider ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for H July 29, 2019 2:06 AM - BizWire Mylan (MYL) in Talks to Merge with Pfizer's (PFE) Off-Patent Drug Business - Reports July 28, 2019 11:42 AM - StreetInsider Pfizer in talks to merge off-patent drugs business with Mylan: source July 27, 2019 9:04 AM - StreetInsider Pfizer (PFE) August option implied volatility into EPS and outlook July 26, 2019 10:56 AM - StreetInsider Eliquis, Orencia sales propel Bristol-Myers to strong second quarter July 25, 2019 10:35 AM - StreetInsider ViiV Healthcare Highlights GEMINI 1 & 2 Studies Through Week 96 Showing 2-Drug Regimen of Dolutegravir plus Lamivudine July 24, 2019 11:26 AM - StreetInsider ViiV Healthcare in Collaboration with Pfizer Inc. (PFE) & Shionogi Ltd. Reports Data from Phase 3 TANGO Study July 24, 2019 11:11 AM - StreetInsider ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV July 24, 2019 11:06 AM - BizWire ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent July 24, 2019 11:06 AM - BizWire GSK raises 2019 earnings expectations after standout quarter for Shingrix July 24, 2019 7:13 AM - StreetInsider Drugmaker GSK ends chairman search with HSBC's Symonds July 24, 2019 5:11 AM - StreetInsider Pfizer (PFE) Reports FDA Approval of RUXIENCE (rituximab-pvvr), a Biosimilar for Certain Cancers and Autoimmune Conditions July 23, 2019 1:50 PM - StreetInsider FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions July 23, 2019 1:48 PM - BizWire ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019 July 22, 2019 12:07 PM - BizWire Novartis raises full-year targets, aims to settle U.S. lawsuit July 18, 2019 1:22 AM - StreetInsider TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimer’s Development, Report Suggests July 17, 2019 11:30 AM - StreetInsider Hong Kong Sports and Leisure Expo opens today July 17, 2019 8:14 AM - StreetInsider Form 4 PFIZER INC For: Jul 15 Filed by: ROGERS DAWN July 16, 2019 7:08 PM - SEC Filing Form 4 PFIZER INC For: Jul 15 Filed by: YOUNG JOHN D July 16, 2019 7:08 PM - SEC Filing Form 4 PFIZER INC For: Jul 15 Filed by: JOHNSON RADY A July 16, 2019 7:08 PM - SEC Filing Form 4 PFIZER INC For: Jul 15 Filed by: BOURLA ALBERT July 16, 2019 7:07 PM - SEC Filing Gilead invests $5 billion to deepen ties with biotech Galapagos July 14, 2019 2:53 PM - StreetInsider Form 4 PFIZER INC For: Jul 10 Filed by: JOHNSON RADY A July 11, 2019 8:06 PM - SEC Filing Form 4 PFIZER INC For: Jul 10 Filed by: ROGERS DAWN July 11, 2019 8:06 PM - SEC Filing Form 4 PFIZER INC For: Jul 10 Filed by: YOUNG JOHN D July 11, 2019 8:06 PM - SEC Filing Form 4 PFIZER INC For: Jul 10 Filed by: BOURLA ALBERT July 11, 2019 8:06 PM - SEC Filing Pfizer (PFE), Lilly (LLY) Merck (MRK) Shares Lower as Biotech Slumps July 11, 2019 9:40 AM - StreetInsider S&P 500, Dow climb as health insurers, financials gain July 11, 2019 7:35 AM - StreetInsider European Commission approves GlaxoSmithKline's (GSK) acquisition of Pfizer's (PFE) Consumer Health Business, subject to conditions July 10, 2019 11:59 AM - StreetInsider GSK, Pfizer (PFE) & Shionogi Ltd. Joint-Owned Company, ViiV Healthcare, Reports Phase III TANGO Study Meets Primary Endpoint July 10, 2019 6:09 AM - StreetInsider ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switch July 10, 2019 2:16 AM - BizWire ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patient July 10, 2019 2:15 AM - BizWire Sarepta Therapeutics (SRPT) Is Pulling Away From Pfizer, PT to $220 At Morgan Stanley July 9, 2019 6:48 AM - StreetInsider Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy July 8, 2019 5:50 AM - StreetInsider Pfizer (PFE) option implied volatility low as shares at upper end of range July 8, 2019 5:43 AM - StreetInsider Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels July 5, 2019 11:15 PM - BizWire Form 4 PFIZER INC For: Jul 02 Filed by: DAMELIO FRANK A July 3, 2019 4:07 PM - SEC Filing ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection July 3, 2019 4:19 AM - BizWire Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board July 2, 2019 2:34 PM - StreetInsider Form 4 PFIZER INC For: Jun 28 Filed by: NARAYEN SHANTANU July 1, 2019 8:56 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: SMITH JAMES C July 1, 2019 8:56 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: KILTS JAMES M July 1, 2019 8:56 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: Echevarria Joseph July 1, 2019 8:56 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: YOUNG JOHN D July 1, 2019 7:45 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: JOHNSON RADY A July 1, 2019 7:45 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: BOURLA ALBERT July 1, 2019 7:45 PM - SEC Filing Form 4 PFIZER INC For: Jun 28 Filed by: ROGERS DAWN July 1, 2019 7:45 PM - SEC Filing Form 4 PFIZER INC For: Jun 27 Filed by: Gottlieb Scott July 1, 2019 6:49 PM - SEC Filing Form 3 PFIZER INC For: Jun 27 Filed by: Gottlieb Scott July 1, 2019 11:17 AM - SEC Filing Pfizer Completes Acquisition of Therachon July 1, 2019 10:00 AM - BizWire Pfizer (PFE) Reports Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment July 1, 2019 8:04 AM - StreetInsider Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis July 1, 2019 8:00 AM - BizWire Pfizer (PFE) Phase 3 Trial of Revatio in Newborns with PPHN Did Not Meet its Primary Efficacy Endpoint June 28, 2019 4:06 PM - StreetInsider Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension June 28, 2019 4:05 PM - BizWire Sarepta surges after Pfizer gene therapy data raises safety concerns June 28, 2019 12:33 PM - StreetInsider Pfizer (PFE) Presents Initial Clinical Data on Phase 1b Gene Therapy Study for DMD June 28, 2019 10:16 AM - StreetInsider Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD) June 28, 2019 10:15 AM - BizWire Pfizer (PFE) DMD Trial Pauses After One Child Hospitalized - Bloomberg June 28, 2019 10:13 AM - StreetInsider Pfizer (PFE) Announces FDA Approval for Its Oncology Biosimilar, ZIRABEV June 28, 2019 7:35 AM - StreetInsider Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr) June 28, 2019 7:33 AM - BizWire UPDATE: Pfizer's (PFE) Zirabev Receives FDA approval June 28, 2019 7:27 AM - StreetInsider Sarepta Therapeutics (SRPT) option implied volatility elevated into data June 28, 2019 5:14 AM - StreetInsider Pfizer names former FDA chief Scott Gottlieb to its board June 27, 2019 5:17 PM - StreetInsider Form 8-K PFIZER INC For: Jun 27 June 27, 2019 5:04 PM - SEC Filing Pfizer (PFE) Declares $0.36 Quarterly Dividend; 3.3% Yield June 27, 2019 4:22 PM - StreetInsider Pfizer (PFE) Reports Election of Dr. Scott Gottlieb to Board June 27, 2019 4:20 PM - StreetInsider Scott Gottlieb Elected to Pfizer’s Board of Directors June 27, 2019 4:17 PM - BizWire Pfizer Declares Third-Quarter 2019 Dividend June 27, 2019 4:15 PM - BizWire UPDATE: Pfizer (PFE) Hits Low as Shares of Large Pharma Names Tank June 26, 2019 2:46 PM - StreetInsider Eli Lilly & Co. (LLY) Trades Near Low, Down 3.7% Amid Biotech Selloff June 26, 2019 12:06 PM - StreetInsider Sarepta Therapeutics (SRPT) June weekly option implied volatility elevated into data June 25, 2019 9:59 AM - StreetInsider Pfizer (PFE) Faces a High Hurdle This Friday to Appear Competitive with Sarepta (SRPT) - Cantor June 25, 2019 7:14 AM - StreetInsider Sarepta Therapeutics (SRPT) June weekly call option implied volatility elevated into data June 24, 2019 10:20 AM - StreetInsider Form 4 PFIZER INC For: Jun 20 Filed by: MACKENZIE ALEXANDER R June 21, 2019 4:10 PM - SEC Filing BioMarin Pharma (BMRN) Reports $15M Milestone Payments from Pfizer (PFE) for TALZENNA® (talazoparib) June 21, 2019 11:34 AM - StreetInsider Pfizer (PFE) Announce EC Approves TALZENNA for Patients with Inherited BRCA-Mutated Locally Advanced June 21, 2019 10:47 AM - StreetInsider European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer June 21, 2019 10:45 AM - BizWire GSK offers concessions to address EU concerns over Pfizer deal June 20, 2019 4:18 AM - StreetInsider Sarepta Therapeutics (SRPT) June weekly option implied volatility bid June 19, 2019 12:18 PM - StreetInsider Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts June 18, 2019 10:00 AM - BizWire Form 4 PFIZER INC For: Jun 14 Filed by: YOUNG JOHN D June 17, 2019 6:20 PM - SEC Filing Form 4 PFIZER INC For: Jun 14 Filed by: ROGERS DAWN June 17, 2019 6:19 PM - SEC Filing Form 4 PFIZER INC For: Jun 14 Filed by: JOHNSON RADY A June 17, 2019 6:19 PM - SEC Filing Form 4 PFIZER INC For: Jun 14 Filed by: BOURLA ALBERT June 17, 2019 6:19 PM - SEC Filing Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:35 PM - SEC Filing Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:12 PM - SEC Filing Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:09 PM - SEC Filing Pfizer (PFE) calls active on Array BioPharma (ARRY) deal June 17, 2019 9:56 AM - StreetInsider Form 8-K PFIZER INC For: Jun 14 June 17, 2019 7:13 AM - SEC Filing Pfizer to Acquire Array BioPharma June 17, 2019 6:54 AM - PR NewsWire Pfizer (PFE) June calls active into acquirng Array BioPharma (ARRY) June 17, 2019 6:53 AM - StreetInsider Pfizer (PFE) to Acquire Array BioPharma (ARRY) in $11.4 Billion Deal, $48/Share June 17, 2019 6:45 AM - StreetInsider Pfizer to Acquire Array BioPharma June 17, 2019 6:45 AM - BizWire Pfizer (PFE) Announces Results from XELJANZ XR ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with JAK Inhibitor June 12, 2019 8:02 AM - StreetInsider Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor June 12, 2019 8:00 AM - BizWire Sarepta Therapeutics (SRPT) option implied volatility increases into data June 10, 2019 11:01 AM - StreetInsider Sarepta Therapeutics (SRPT) June weekly option implied volatility bid June 7, 2019 10:52 AM - StreetInsider Sarepta Therapeutics (SRPT) July IV bid June 6, 2019 5:23 AM - StreetInsider Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development June 5, 2019 1:30 PM - BizWire Sarepta Therapeutics (SRPT) July option implied volatility elevated into data June 5, 2019 9:59 AM - StreetInsider Sarepta Therapeutics (SRPT) Volatility Likely Around PF-06939926 (DMD) Data on 6/28 - Morgan Stanley June 5, 2019 9:31 AM - StreetInsider Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer June 5, 2019 7:06 AM - StreetInsider Morgan Stanley Resumes Pfizer (PFE) at Overweight, Sees Growth Acceleration on Horizon June 4, 2019 7:40 AM - StreetInsider Form 4 PFIZER INC For: May 31 Filed by: JOHNSON RADY A June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: ROGERS DAWN June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: YOUNG JOHN D June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: BOURLA ALBERT June 3, 2019 9:36 PM - SEC Filing Matinas BioPharma to Present at the 9th Annual LD Micro Invitational June 3, 2019 8:06 AM - StreetInsider Matinas BioPharma to Present at the 9th Annual LD Micro Invitational June 3, 2019 8:05 AM - Globe NewsWire Goldman Sachs Starts Pfizer (PFE) at Conviction Buy May 28, 2019 2:45 AM - StreetInsider Pfizer (PFE) Phase 3 Trial of LYRICA in PGTC Seizures Did Not Meet its Primary Endpoint May 24, 2019 4:01 PM - StreetInsider Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures May 24, 2019 4:00 PM - BizWire Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research May 21, 2019 8:00 AM - BizWire Full Article List